Choline and bone health

Choline supplementation in postmenopausal women: effects on bone health and risk markers for cardiovascular disease (CVD) - a randomised double-blind placebo-controlled intervention trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN82708510

Enrollment

Registered

2011-01-13

Start date

2005-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone health, cardiovascular disease Circulatory System Cardiovascular disease

Interventions

Patients are randomised to receive either 12 weeks of 2.5 g/d of choline bitartrate (1 g choline) or placebo (2.5 g/d tartaric acid). The duration of follow up was 12 weeks with volunteers sampled at

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 50 - 70 years 2. Independently mobile 3. Postmenopausal (menopausal status defined as at least 6 months of amenorrhoea within the past year)

Exclusion criteria

Exclusion criteria: 1. Smoking 2. Body mass index (BMI) greater than 35 kg/m^2 3. Hepatic or renal disease 4. Gastrointestinal disease 5. Endocrine or metabolic abnormalities 6. Use of drugs or dietary supplements known to influence B vitamin or choline status or metabolism 7. Haematological disorder 8. Serum vitamin B-12 concentration less than 111pmol/l or serum creatinine concentration greater than or equal to 130 umol/l

Design outcomes

Primary

Measure	Time frame
Choline status, measured at baseline, week 6 and week 12.	—

Secondary

Measure	Time frame
Measured at baseline, week 6 and week 12: 1. B vitamin and betaine status 2. Plasma homocysteine 3. Bone turnover markers	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026